Integrated DNA Technologies launches xGen cancer panel

Integrated DNA Technologies has announced the launch of the xGen acute myeloid leukaemia cancer panel, an advanced next-generation sequencing product.

Consisting of 11,743 xGen Lockdown Probes, this is the first cancer panel from the manufacturer and targets more than 260 clinically relevant genes that have been found to be linked to this form of leukaemia.

It is used for enriching the genome for regions of interest before carrying out sequencing, meaning it can be used to study disease occurrence and progression and help with the development of better targeted therapies.

The launch of this product continues the recent success of the xGen product line, an area in which the company has invested a significant amount of resources.

Ibrahim Jivanjee, product manager for next-generation sequencing at Integrated DNA Technologies, said: "The launch of our first cancer panel has been a significant milestone, with early collaborators demonstrating its potential for use in patient diagnosis and monitoring."

The firm earned a positive testimony for the effectiveness of its xGen Lockdown Probes from the University of Texas at Austin last month.